Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Kyowa Kirin brings global reach to Kura’s menin program via licensing deal

Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more

November 26, 2024 12:24 AM UTC

With a pivotal readout looming in early 2025, Kura has tapped Kyowa Kirin as a global partner for its menin inhibitor for acute myelogenous leukemia, adding $330 million up front to its balance sheet with the potential for more near-term milestones to follow.

Kura Oncology Inc. (NASDAQ:KURA) expects data within the next several weeks from the registrational Phase II portion of its KOMET-1 trial of zeftomenib, evaluating the candidate in patients with relapsed or refractory NPM1-mutant AML. Ahead of that readout, Kyowa Kirin Co. Ltd. (Tokyo:4151) has acquired all ex-U.S. commercialization rights to the program, as well as a 50-50 profit share and co-development rights inside the U.S...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article